nach oben

Current Neurology and Neuroscience Reports

20.04.2024 | Review

Epidemiology of Parkinson’s Disease: An Update

verfasst von: Juan R Deliz, Caroline M. Tanner, Paulina Gonzalez-Latapi

Erschienen in: Current Neurology and Neuroscience Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In recent decades, epidemiological understanding of Parkinson disease (PD) has evolved significantly. Major discoveries in genetics and large epidemiological investigations have provided a better understanding of the genetic, behavioral, and environmental factors that play a role in the pathogenesis and progression of PD. In this review, we provide an epidemiological update of PD with a particular focus on advances in the last five years of published literature.

Recent Findings

We include an overview of PD pathophysiology, followed by a detailed discussion of the known distribution of disease and varied determinants of disease. We describe investigations of risk factors for PD, and provide a critical summary of current knowledge, knowledge gaps, and both clinical and research implications. We emphasize the need to characterize the epidemiology of the disease in diverse populations.

Summary

Despite increasing understanding of PD epidemiology, recent paradigm shifts in the conceptualization of PD as a biological entity will also impact epidemiological research moving forward and guide further work in this field.

Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–36. https://doi.org/10.1176/jnp.14.2.223.CrossRefPubMed

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–601. https://doi.org/10.1002/mds.26424.CrossRefPubMed

Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42(1):33–50. https://doi.org/10.1111/nan.12298.CrossRefPubMed

Fullard ME, Morley JF, Duda JE. Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease. Neurosci Bull. 2017;33(5):515–25. https://doi.org/10.1007/s12264-017-0170-x.CrossRefPubMedPubMedCentral

Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062–7. https://doi.org/10.1002/mds.21076.CrossRefPubMed

Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008;63(2):167–73. https://doi.org/10.1002/ana.21291.CrossRefPubMed

Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57(3):456–62. https://doi.org/10.1212/wnl.57.3.456.CrossRefPubMed

Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22(11):1581–6. https://doi.org/10.1002/mds.21560.CrossRefPubMed

Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(7):710–6. https://doi.org/10.1136/jnnp-2015-311680.CrossRefPubMed

10.

Camacho-Soto A, Gross A, Searles Nielsen S, Dey N, Racette BA. Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. Parkinsonism Relat Disord. 2018;50:23–8. https://doi.org/10.1016/j.parkreldis.2018.02.008.CrossRefPubMedPubMedCentral

11.

Benarroch EE. Locus coeruleus. Cell Tissue Res. 2018;373(1):221–32. https://doi.org/10.1007/s00441-017-2649-1.CrossRefPubMed

12.

Frouni I, Kwan C, Belliveau S, Huot P. Cognition and serotonin in Parkinson's disease. Prog Brain Res. 2022;269(1):373–403. https://doi.org/10.1016/bs.pbr.2022.01.013.CrossRefPubMed

13.

Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1–12. https://doi.org/10.1016/j.cger.2019.08.002.CrossRefPubMed

14.

Barazzuol L, Giamogante F, Brini M, Cali T. PINK1/Parkin Mediated Mitophagy, Ca(2+) Signalling, and ER-Mitochondria Contacts in Parkinson's Disease. Int J Mol Sci. 2020;21(5) https://doi.org/10.3390/ijms21051772.

15.

Borsche M, Pereira SL, Klein C, Grunewald A. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis. 2021;11(1):45–60. https://doi.org/10.3233/JPD-201981.CrossRefPubMedPubMedCentral

16.

Tansey MG, Romero-Ramos M. Immune system responses in Parkinson's disease: Early and dynamic. Eur J Neurosci. 2019;49(3):364–83. https://doi.org/10.1111/ejn.14290.CrossRefPubMed

17.

Gonzalez-Latapi P, Marras C. Epidemiological Evidence for an Immune Component of Parkinson's Disease. J Parkinsons Dis. 2022;12(s1):S29–43. https://doi.org/10.3233/JPD-223180.CrossRefPubMedPubMedCentral

18.

Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–17. https://doi.org/10.1016/S1474-4422(23)00109-6.CrossRefPubMedPubMedCentral

19.

Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orru CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou WQ. Skin alpha-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020;78(1):1–11. https://doi.org/10.1001/jamaneurol.2020.3311.CrossRefPubMedPubMedCentral

20.

Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T. Proposal for a Biologic Staging System of Parkinson's Disease. J Parkinsons Dis. 2023;13(3):297–309. https://doi.org/10.3233/JPD-225111.CrossRefPubMedPubMedCentral

21.

Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90. https://doi.org/10.1002/mds.25945.CrossRefPubMed

22.

Group, G. B. D. N. D. C. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97. https://doi.org/10.1016/S1474-4422(17)30299-5.CrossRef

23.

Collaborators, G. B. D. P. s. D. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53. https://doi.org/10.1016/S1474-4422(18)30295-3.CrossRef

24.

Llibre-Guerra JJ, Prina M, Sosa AL, Acosta D, Jimenez-Velazquez IZ, Guerra M, Salas A, Llibre-Guerra JC, Valvuerdi A, Peeters G, Ziegemeier E, Acosta I, Tanner C, Juncos J, Llibre Rodriguez JJ. Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study. Lancet Reg Health Am. 2022;7:None. https://doi.org/10.1016/j.lana.2021.100136.CrossRefPubMed

25.

Williams U, Bandmann O, Walker R. Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. J Mov Disord. 2018;11(2):53–64. https://doi.org/10.14802/jmd.17028.CrossRefPubMedPubMedCentral

26.

Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, Van Den Eeden SK, Tanner CM, Marras C, Parkinson's Foundation, P G. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022;8(1):170. https://doi.org/10.1038/s41531-022-00410-y.CrossRefPubMedPubMedCentral

27.

Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM, Parkinson's Foundation, P G. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018;4:21. https://doi.org/10.1038/s41531-018-0058-0.CrossRefPubMedPubMedCentral

28.

Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3–8. https://doi.org/10.3233/JPD-181474.CrossRefPubMedPubMedCentral

29.

Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143–51. https://doi.org/10.1159/000275491.CrossRefPubMedPubMedCentral

30.

Bailey M, Anderson S, Hall DA. Parkinson's Disease in African Americans: A Review of the Current Literature. J Parkinsons Dis. 2020;10(3):831–41. https://doi.org/10.3233/JPD-191823.CrossRefPubMedPubMedCentral

31.

Bandres-Ciga S, Black, & African American Connections to Parkinson's Disease Study, G. Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics. Mov Disord. 2022;37(7):1559–61. https://doi.org/10.1002/mds.29042.CrossRefPubMedPubMedCentral

32.

Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, Levine KS, Abubakar SA, Achoru CO, Vitale D, Adeniji OA, Agabi OP, Koretsky MJ, Agulanna U, Hall DA, Akinyemi RO, Xie T, Ali MW, Shamim EA, et al. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023; https://doi.org/10.1016/S1474-4422(23)00283-1.

33.

Loesch DP, Horimoto A, Heilbron K, Sarihan EI, Inca-Martinez M, Mason E, Cornejo-Olivas M, Torres L, Mazzetti P, Cosentino C, Sarapura-Castro E, Rivera-Valdivia A, Medina AC, Dieguez E, Raggio V, Lescano A, Tumas V, Borges V, Ferraz HB, et al. Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. Ann Neurol. 2021;90(3):353–65. https://doi.org/10.1002/ana.26153.CrossRefPubMedPubMedCentral

34.

van Rensburg ZJ, Abrahams S, Chetty D, Step K, Acker D, Lombard CJ, Elbaz A, Carr J, Bardien S. The South African Parkinson's Disease Study Collection. Mov Disord. 2022;37(1):230–2. https://doi.org/10.1002/mds.28828.CrossRefPubMed

35.

Abraham DS, Gruber-Baldini AL, Magder LS, McArdle PF, Tom SE, Barr E, Schrader K, Shulman LM. Sex differences in Parkinson's disease presentation and progression. Parkinsonism Relat Disord. 2019;69:48–54. https://doi.org/10.1016/j.parkreldis.2019.10.019.CrossRefPubMedPubMedCentral

36.

Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson's disease. Front Neuroendocrinol. 2014;35(3):370–84. https://doi.org/10.1016/j.yfrne.2014.02.002.CrossRefPubMedPubMedCentral

37.

Le Guen Y, Napolioni V, Belloy ME, Yu E, Krohn L, Ruskey JA, Gan-Or Z, Kennedy G, Eger SJ, Greicius MD. Common X-Chromosome Variants Are Associated with Parkinson Disease Risk. Ann Neurol. 2021;90(1):22–34. https://doi.org/10.1002/ana.26051.CrossRefPubMedPubMedCentral

38.

Leal TP, Rao SC, French-Kwawu JN, Gouveia MH, Borda V, Bandres-Ciga S, Inca-Martinez M, Mason EA, Horimoto A, Loesch DP, Sarihan EI, Cornejo-Olivas MR, Torres LE, Mazzetti-Soler PE, Cosentino C, Sarapura-Castro EH, Rivera-Valdivia A, Medina AC, Dieguez EM, et al. X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease. Mov Disord. 2023;38(9):1625–35. https://doi.org/10.1002/mds.29508.CrossRefPubMed

39.

Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis. 2019;9(3):501–15. https://doi.org/10.3233/JPD-191683.CrossRefPubMedPubMedCentral

40.

Patel R, Kompoliti K. Sex and Gender Differences in Parkinson's Disease. Neurol Clin. 2023;41(2):371–9. https://doi.org/10.1016/j.ncl.2022.12.001.CrossRefPubMed

41.

Vaidya B, Dhamija K, Guru P, Sharma SS. Parkinson's disease in women: Mechanisms underlying sex differences. Eur J Pharmacol. 2021;895:173862. https://doi.org/10.1016/j.ejphar.2021.173862.CrossRefPubMed

42.

Gan-Or Z, Leblond CS, Mallett V, Orr-Urtreger A, Dion PA, Rouleau GA. LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. Parkinsonism Relat Disord. 2015;21(7):778–82. https://doi.org/10.1016/j.parkreldis.2015.05.002.CrossRefPubMed

43.

Dahodwala N, Shah K, He Y, Wu SS, Schmidt P, Cubillos F, Willis AW. Sex disparities in access to caregiving in Parkinson disease. Neurology. 2018;90(1):e48–54. https://doi.org/10.1212/WNL.0000000000004764.CrossRefPubMedPubMedCentral

44.

Picillo M, LaFontant DE, Bressman S, Caspell-Garcia C, Coffey C, Cho HR, Burghardt EL, Dahodwala N, Saunders-Pullman R, Tanner CM, Amara AW, Parkinson's Progression Markers, I. Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease. J Parkinsons Dis. 2022;12(1):421–36. https://doi.org/10.3233/JPD-212892.CrossRefPubMedPubMedCentral

45.

Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570–84. https://doi.org/10.1111/ane.12796.CrossRefPubMed

46.

Ortega RA, Wang C, Raymond D, Bryant N, Scherzer CR, Thaler A, Alcalay RN, West AB, Mirelman A, Kuras Y, Marder KS, Giladi N, Ozelius LJ, Bressman SB, Saunders-Pullman R. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. JAMA Netw Open. 2021;4(4):e215845. https://doi.org/10.1001/jamanetworkopen.2021.5845.CrossRefPubMedPubMedCentral

47.

Lin CR, Rosendale N, Deeb W. Expanding sexual and gender minority research in movement disorders: More than awareness and acceptance. Parkinsonism Relat Disord. 2021;87:162–5. https://doi.org/10.1016/j.parkreldis.2021.05.019.CrossRefPubMed

48.

Angelopoulou E, Paudel YN, Papageorgiou SG, Piperi C. Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review. Brain Sci. 2022;12(2) https://doi.org/10.3390/brainsci12020175.

49.

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011;119(6):866–72. https://doi.org/10.1289/ehp.1002839.CrossRefPubMedPubMedCentral

50.

Paul KC, Krolewski RC, Lucumi Moreno E, Blank J, Holton KM, Ahfeldt T, Furlong M, Yu Y, Cockburn M, Thompson LK, Kreymerman A, Ricci-Blair EM, Li YJ, Patel HB, Lee RT, Bronstein J, Rubin LL, Khurana V, Ritz B. A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. Nat Commun. 2023;14(1):2803. https://doi.org/10.1038/s41467-023-38215-z.CrossRefPubMedPubMedCentral

51.

Li S, Ritz B, Gong Y, Cockburn M, Folle AD, Del Rosario I, Yu Y, Zhang K, Castro E, Keener AM, Bronstein J, Paul KC. Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California. Sci Total Environ. 2023;864:160851. https://doi.org/10.1016/j.scitotenv.2022.160851.CrossRefPubMed

52.

Liu M, Shin EJ, Dang DK, Jin CH, Lee PH, Jeong JH, Park SJ, Kim YS, Xing B, Xin T, Bing G, Kim HC. Trichloroethylene and Parkinson's Disease: Risk Assessment. Mol Neurobiol. 2018;55(7):6201–14. https://doi.org/10.1007/s12035-017-0830-x.CrossRefPubMed

53.

Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, Brown EG, Tanner CM. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol. 2023;80(7):673–81. https://doi.org/10.1001/jamaneurol.2023.1168.CrossRefPubMed

54.

Ritz B, Lee PC, Hansen J, Lassen CF, Ketzel M, Sorensen M, Raaschou-Nielsen O. Traffic-Related Air Pollution and Parkinson's Disease in Denmark: A Case-Control Study. Environ Health Perspect. 2016;124(3):351–6. https://doi.org/10.1289/ehp.1409313.CrossRefPubMed

55.

Karakis I, Yarza S, Zlotnik Y, Ifergane G, Kloog I, Grant-Sasson K, Novack L. Contribution of Solar Radiation and Pollution to Parkinson's Disease. Int J Environ Res Public Health. 2023;20(3) https://doi.org/10.3390/ijerph20032254.

56.

Cole-Hunter T, Zhang J, So R, Samoli E, Liu S, Chen J, Strak M, Wolf K, Weinmayr G, Rodopolou S, Remfry E, de Hoogh K, Bellander T, Brandt J, Concin H, Zitt E, Fecht D, Forastiere F, Gulliver J, et al. Long-term air pollution exposure and Parkinson's disease mortality in a large pooled European cohort: An ELAPSE study. Environ Int. 2023;171:107667. https://doi.org/10.1016/j.envint.2022.107667.CrossRefPubMed

57.

Yuan X, Yang Y, Liu C, Tian Y, Xia D, Liu Z, Pan L, Xiong M, Xiong J, Meng L, Zhang Z, Ye K, Jiang H, Zhang Z. Fine Particulate Matter Triggers alpha-Synuclein Fibrillization and Parkinson-like Neurodegeneration. Mov Disord. 2022;37(9):1817–30. https://doi.org/10.1002/mds.29181.CrossRefPubMed

58.

Rumrich IK, Lin J, Korhonen A, Frohn LM, Geels C, Brandt J, Hartikainen S, Hanninen O, Tolppanen AM. Long-term exposure to low-level particulate air pollution and Parkinson's disease diagnosis - A Finnish register-based study. Environ Res. 2023;229:115944. https://doi.org/10.1016/j.envres.2023.115944.CrossRefPubMed

59.

De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson's Disease: An Environmental Agenda. J Parkinsons Dis. 2022;12(1):45–68. https://doi.org/10.3233/JPD-212922.CrossRefPubMedPubMedCentral

60.

Whiteneck GG, Cuthbert JP, Corrigan JD, Bogner JA. Prevalence of Self-Reported Lifetime History of Traumatic Brain Injury and Associated Disability: A Statewide Population-Based Survey. J Head Trauma Rehabil. 2016;31(1):E55–62. https://doi.org/10.1097/HTR.0000000000000140.CrossRefPubMed

61.

Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, Borlongan CV. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J Cell Physiol. 2015;230(5):1024–32. https://doi.org/10.1002/jcp.24830.CrossRefPubMedPubMedCentral

62.

Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013;28(9):1222–9. https://doi.org/10.1002/mds.25458.CrossRefPubMed

63.

Kenborg L, Rugbjerg K, Lee PC, Ravnskjaer L, Christensen J, Ritz B, Lassen CF. Head injury and risk for Parkinson disease: results from a Danish case-control study. Neurology. 2015;84(11):1098–103. https://doi.org/10.1212/WNL.0000000000001362.CrossRefPubMedPubMedCentral

64.

Bruce HJ, Tripodis Y, McClean M, Korell M, Tanner CM, Contreras B, Gottesman J, Kirsch L, Karim Y, Martin B, Palmisano J, Abdolmohammadi B, Shih LC, Stein TD, Stern RA, Adler CH, Mez J, Nowinski C, McKee AC, Alosco ML. American Football Play and Parkinson Disease Among Men. JAMA Netw Open. 2023;6(8):e2328644. https://doi.org/10.1001/jamanetworkopen.2023.28644.CrossRefPubMedPubMedCentral

65.

Gardner RC, Burke JF, Nettiksimmons J, Goldman S, Tanner CM, Yaffe K. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol. 2015;77(6):987–95. https://doi.org/10.1002/ana.24396.CrossRefPubMedPubMedCentral

66.

Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ. 2008;337:a2494. https://doi.org/10.1136/bmj.a2494.CrossRefPubMedPubMedCentral

67.

Ilmaniemi S, Tolppanen AM, Herukka SK, Hartikainen P, Hartikainen S. Incidence and outcomes of head injuries in people with and without Parkinson disease. Eur J Neurol. 2023;30(6):1648–57. https://doi.org/10.1111/ene.15782.CrossRefPubMed

68.

Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. 2017;89(1):46–52. https://doi.org/10.1212/WNL.0000000000004057.CrossRefPubMedPubMedCentral

69.

Olsson E, Byberg L, Hoijer J, Kilander L, Larsson SC. Milk and Fermented Milk Intake and Parkinson's Disease: Cohort Study. Nutrients. 2020;12(9) https://doi.org/10.3390/nu12092763.

70.

Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, Grover S, Mohamed O, Portugal B, May P, Bobbili DR, Radivojkov-Blagojevic M, Lichtner P, Singleton AB, Hernandez DG, Edsall C, Mellick GD, Zimprich A, Pirker W, Rogaeva E, Lang AE, et al. Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Mov Disord. 2022;37(4):857–64. https://doi.org/10.1002/mds.28902.CrossRefPubMed

71.

Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JAG. Alcohol consumption and risk for Parkinson's disease: a systematic review and meta-analysis. J Neurol. 2019;266(8):1821–34. https://doi.org/10.1007/s00415-018-9032-3.CrossRefPubMed

72.

Shao C, Wang X, Wang P, Tang H, He J, Wu N. Parkinson's Disease Risk and Alcohol Intake: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Front Nutr. 2021;8:709846. https://doi.org/10.3389/fnut.2021.709846.CrossRefPubMedPubMedCentral

73.

Kim IY, Yang TO, Heath AK, Simpson RF, Reeves GK, Green J, Floud S, Brown A, Hunter DJ, Beral V, Sweetland S, Million Women Study, C. Alcohol intake and Parkinson's disease risk in the million women study. Mov Disord. 2020;35(3):443–9. https://doi.org/10.1002/mds.27933.CrossRefPubMed

74.

Peters S, Gallo V, Vineis P, Middleton LT, Forsgren L, Sacerdote C, Sieri S, Kyrozis A, Chirlaque MD, Zamora-Ros R, Hansson O, Petersson J, Katzke V, Kuhn T, Mokoroa O, Masala G, Ardanaz E, Panico S, Bergmann MM, et al. Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. Mov Disord. 2020;35(7):1258–63. https://doi.org/10.1002/mds.28039.CrossRefPubMedPubMedCentral

75.

Kim R, Yoo D, Jung YJ, Han K, Lee JY. Sex differences in smoking, alcohol consumption, and risk of Parkinson's disease: A nationwide cohort study. Parkinsonism Relat Disord. 2020;71:60–5. https://doi.org/10.1016/j.parkreldis.2019.12.006.CrossRefPubMed

76.

Aune D, Schlesinger S, Mahamat-Saleh Y, Zheng B, Udeh-Momoh CT, Middleton LT. Diabetes mellitus, prediabetes and the risk of Parkinson's disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. Eur J Epidemiol. 2023;38(6):591–604. https://doi.org/10.1007/s10654-023-00970-0.CrossRefPubMedPubMedCentral

77.

Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S, Gan-Or Z, Noyce AJ. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Mov Disord. 2021;36(6):1420–9. https://doi.org/10.1002/mds.28551.CrossRefPubMedPubMedCentral

78.

Cullinane PW, de Pablo Fernandez E, Konig A, Outeiro TF, Jaunmuktane Z, Warner TT. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts. Mov Disord. 2023;38(2):162–77. https://doi.org/10.1002/mds.29298.CrossRefPubMed

79.

Nam GE, Kim SM, Han K, Kim NH, Chung HS, Kim JW, Han B, Cho SJ, Yu JH, Park YG, Choi KM. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med. 2018;15(8):e1002640. https://doi.org/10.1371/journal.pmed.1002640.CrossRefPubMedPubMedCentral

80.

Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, Vijiaratnam N, Girges C, Ben-Shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The Impact of Type 2 Diabetes in Parkinson's Disease. Mov Disord. 2022;37(8):1612–23. https://doi.org/10.1002/mds.29122.CrossRefPubMedPubMedCentral

81.

Fang F, Zhan Y, Hammar N, Shen X, Wirdefeldt K, Walldius G, Mariosa D. Lipids, Apolipoproteins, and the Risk of Parkinson Disease. Circ Res. 2019;125(6):643–52. https://doi.org/10.1161/CIRCRESAHA.119.314929.CrossRefPubMed

82.

Fu X, Wang Y, He X, Li H, Liu H, Zhang X. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease. Lipids Health Dis. 2020;19(1):97. https://doi.org/10.1186/s12944-020-01284-w.CrossRefPubMedPubMedCentral

83.

Paul KC, Chuang YH, Shih IF, Keener A, Bordelon Y, Bronstein JM, Ritz B. The association between lifestyle factors and Parkinson's disease progression and mortality. Mov Disord. 2019;34(1):58–66. https://doi.org/10.1002/mds.27577.CrossRefPubMedPubMedCentral

84.

Reichmann H, Csoti I, Koschel J, Lorenzl S, Schrader C, Winkler J, Wullner U. Life style and Parkinson's disease. J Neural Transm (Vienna). 2022;129(9):1235–45. https://doi.org/10.1007/s00702-022-02509-1.CrossRefPubMed

85.

Kim IY, O'Reilly EJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018;90(19):e1646–53. https://doi.org/10.1212/WNL.0000000000005473.CrossRefPubMedPubMedCentral

86.

Dominguez-Baleon C, Ong JS, Scherzer CR, Renteria ME, Dong X. Understanding the effect of smoking and drinking behavior on Parkinson's disease risk: a Mendelian randomization study. Sci Rep. 2021;11(1):13980. https://doi.org/10.1038/s41598-021-93105-y.CrossRefPubMedPubMedCentral

87.

Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, Peto R. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology. 2020;94(20):e2132–8. https://doi.org/10.1212/WNL.0000000000009437.CrossRefPubMedPubMedCentral

88.

Carvajal-Oliveros A, Dominguez-Baleon C, Sanchez-Diaz I, Zambrano-Tipan D, Hernandez-Vargas R, Campusano JM, Narvaez-Padilla V, Reynaud E. Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment. PLoS One. 2023;18(3):e0282348. https://doi.org/10.1371/journal.pone.0282348.CrossRefPubMedPubMedCentral

89.

Olsen AL, Clemens SG, Feany MB. Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila. Mov Disord. 2023;38(2):244–55. https://doi.org/10.1002/mds.29283.CrossRefPubMed

90.

Mannett BT, Capt BC, Pearman K, Buhlman LM, VandenBrooks JM, Call GB. Nicotine Has a Therapeutic Window of Effectiveness in a Drosophila melanogaster Model of Parkinson's Disease. Parkinsons Dis. 2022;2022:9291077. https://doi.org/10.1155/2022/9291077.CrossRefPubMedPubMedCentral

91.

Biswas S, Bagchi A. Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinson's Disease. Appl Biochem Biotechnol. 2023;195(1):639–54. https://doi.org/10.1007/s12010-022-04155-5.CrossRefPubMed

92.

Chen SQ, Wang ZS, Ma YX, Zhang W, Lu JL, Liang YR, Zheng XQ. Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases. Molecules. 2018;23(3) https://doi.org/10.3390/molecules23030512.

93.

Ikram M, Park TJ, Ali T, Kim MO. Antioxidant and Neuroprotective Effects of Caffeine against Alzheimer's and Parkinson's Disease: Insight into the Role of Nrf-2 and A2AR Signaling. Antioxidants (Basel). 2020;9(9) https://doi.org/10.3390/antiox9090902.

94.

Manalo RVM, Medina PMB. Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic Caenorhabditis elegans. Front Neurosci. 2018;12:137. https://doi.org/10.3389/fnins.2018.00137.CrossRefPubMedPubMedCentral

95.

Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020;10(2):505–10. https://doi.org/10.3233/JPD-191882.CrossRefPubMedPubMedCentral

96.

Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020;95(24):e3428–37. https://doi.org/10.1212/WNL.0000000000010863.CrossRefPubMedPubMedCentral

97.

Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018;90(5):e404–11. https://doi.org/10.1212/WNL.0000000000004888.CrossRefPubMedPubMedCentral

98.

Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord. 2020;35(8):1438–47. https://doi.org/10.1002/mds.28068.CrossRefPubMedPubMedCentral

99.

Hong CT, Chan L, Bai CH. The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis. Nutrients. 2020;12(6) https://doi.org/10.3390/nu12061860.

100.

Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Front Aging Neurosci. 2020;12:186. https://doi.org/10.3389/fnagi.2020.00186.CrossRefPubMedPubMedCentral

101.

Fang X, Han D, Cheng Q, Zhang P, Zhao C, Min J, Wang F. Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(5):e182421. https://doi.org/10.1001/jamanetworkopen.2018.2421.CrossRefPubMedPubMedCentral

102.

Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, et al. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022;23(1):855. https://doi.org/10.1186/s13063-022-06703-0.CrossRefPubMedPubMedCentral

103.

Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018;75(2):219–26. https://doi.org/10.1001/jamaneurol.2017.3517.CrossRefPubMed

104.

Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. 2019;93(23):e2157–69. https://doi.org/10.1212/WNL.0000000000008567.CrossRefPubMedPubMedCentral

105.

De Miguel, Z., Khoury, N., Betley, M. J., Lehallier, B., Willoughby, D., Olsson, N., Yang, A. C., Hahn, O., Lu, N., Vest, R. T., Bonanno, L. N., Yerra, L., Zhang, L., Saw, N. L., Fairchild, J. K., Lee, D., Zhang, H., McAlpine, P. L., Contrepois, K., . . . Wyss-Coray, T. (2021). Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature, 600(7889), 494-499. https://doi.org/10.1038/s41586-021-04183-xCrossRefPubMedPubMedCentral

106.

Darweesh SKL, De Vries NM, Helmich RC, Verbeek MM, Schwarzschild MA, Bloem BR. Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease. J Parkinsons Dis. 2022;12(5):1419–22. https://doi.org/10.3233/JPD-223216.CrossRefPubMedPubMedCentral

107.

Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson's disease. Mov Disord. 2012;27(6):771–4. https://doi.org/10.1002/mds.24918.CrossRefPubMedPubMedCentral

108.

Maraki MI, Yannakoulia M, Stamelou M, Stefanis L, Xiromerisiou G, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Anastasiou CA, Simopoulou E, Scarmeas N. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Mov Disord. 2019;34(1):48–57. https://doi.org/10.1002/mds.27489.CrossRefPubMed

109.

Yin W, Lof M, Pedersen NL, Sandin S, Fang F. Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study. Mov Disord. 2021;36(1):255–60. https://doi.org/10.1002/mds.28314.CrossRefPubMed

110.

Metcalfe-Roach A, Yu AC, Golz E, Cirstea M, Sundvick K, Kliger D, Foulger LH, Mackenzie M, Finlay BB, Appel-Cresswell S. MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease. Mov Disord. 2021;36(4):977–84. https://doi.org/10.1002/mds.28464.CrossRefPubMedPubMedCentral

111.

Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson disease. Neurology. 2020;95(15):e2095–108. https://doi.org/10.1212/WNL.0000000000010523.CrossRefPubMedPubMedCentral

112.

Zhang X, Xu J, Liu Y, Chen S, Wu S, Gao X. Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults. Mov Disord. 2022;37(12):2367–75. https://doi.org/10.1002/mds.29208.CrossRefPubMed

113.

Solch RJ, Aigbogun JO, Voyiadjis AG, Talkington GM, Darensbourg RM, O'Connell S, Pickett KM, Perez SR, Maraganore DM. Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: A systematic review. J Neurol Sci. 2022;434:120166. https://doi.org/10.1016/j.jns.2022.120166.CrossRefPubMed

114.

Flores-Torres MH, Christine CW, Bjornevik K, Molsberry SA, Hung AY, Healy BC, Blacker D, Schwarzschild MA, Ascherio A. Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men. Mov Disord. 2023;38(5):866–79. https://doi.org/10.1002/mds.29383.CrossRefPubMed

115.

Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012;78(15):1138–45. https://doi.org/10.1212/WNL.0b013e31824f7fc4.CrossRefPubMedPubMedCentral

116.

Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. 2022;98(10):e1064–76. https://doi.org/10.1212/WNL.0000000000013275.CrossRefPubMedPubMedCentral

117.

Jeong SM, Jang W, Shin DW. Association of statin use with Parkinson's disease: Dose-response relationship. Mov Disord. 2019;34(7):1014–21. https://doi.org/10.1002/mds.27681.CrossRefPubMed

118.

Yan J, Qiao L, Tian J, Liu A, Wu J, Huang J, Shen M, Lai X. Effect of statins on Parkinson's disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(12):e14852. https://doi.org/10.1097/MD.0000000000014852.CrossRefPubMed

119.

Chang YH, Yen SJ, Chang YH, Wu WJ, Lin KD. Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. Eur J Neurol. 2021;28(2):430–7. https://doi.org/10.1111/ene.14542.CrossRefPubMed

120.

Investigators NET, i. P. D. F.-Z. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14(8):795–803. https://doi.org/10.1016/S1474-4422(15)00144-1.CrossRef

121.

Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev. 2011;(11):CD008454. https://doi.org/10.1002/14651858.CD008454.pub2.

122.

San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schule B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, et al. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. Mov Disord. 2020;35(10):1755–64. https://doi.org/10.1002/mds.28189.CrossRefPubMed

123.

Brakedal B, Tzoulis C, Tysnes OB, Haugarvoll K. NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. PLoS One. 2021;16(9):e0256602. https://doi.org/10.1371/journal.pone.0256602.CrossRefPubMedPubMedCentral

124.

Gabbert C, Konig IR, Luth T, Kolms B, Kasten M, Vollstedt EJ, Balck A, Grunewald A, Klein C, Trinh J. Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson's disease. J Neurol. 2022;269(8):4195–203. https://doi.org/10.1007/s00415-022-11041-x.CrossRefPubMedPubMedCentral

125.

Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W. beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease. Mov Disord. 2018;33(9):1465–71. https://doi.org/10.1002/mds.108.CrossRefPubMed

126.

Hopfner F, Hoglinger GU, Kuhlenbaumer G, Pottegard A, Wod M, Christensen K, Tanner CM, Deuschl G. beta-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurol. 2020;19(3):247–54. https://doi.org/10.1016/S1474-4422(19)30400-4.CrossRefPubMed

127.

Hopfner F, Wod M, Hoglinger GU, Blaabjerg M, Rosler TW, Kuhlenbaumer G, Christensen K, Deuschl G, Pottegard A. Use of beta2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology. 2019;93(2):e135–42. https://doi.org/10.1212/WNL.0000000000007694.CrossRefPubMed

128.

Saengphatrachai W, Praditukrit K, Owattanapanich W, Pitakpatapee Y, Srivanitchapoom P. The association between developing Parkinson's disease and beta-Adrenoceptor acting agents use: A systematic review and meta-analysis. J Neurol Sci. 2021;430:120009. https://doi.org/10.1016/j.jns.2021.120009.CrossRefPubMed

129.

Jiang Z, Gu XJ, Su WM, Duan QQ, Ren YL, Li JR, Chi LY, Wang Y, Cao B, Chen YP. Protective effect of antihypertensive drugs on the risk of Parkinson's disease lacks causal evidence from mendelian randomization. Front Pharmacol. 2023;14:1107248. https://doi.org/10.3389/fphar.2023.1107248.CrossRefPubMedPubMedCentral

130.

Rees K, Stowe R, Patel S, Ives N, Breen K, Ben-Shlomo Y, Clarke CE. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. Cochrane Database Syst Rev. 2011;(11):CD008535. https://doi.org/10.1002/14651858.CD008535.pub2.

131.

Ejma M, Madetko N, Brzecka A, Guranski K, Alster P, Misiuk-Hojlo M, Somasundaram SG, Kirkland CE, Aliev G. The Links between Parkinson's Disease and Cancer. Biomedicines. 2020;8(10) https://doi.org/10.3390/biomedicines8100416.

132.

Lee JYS, Ng JH, Saffari SE, Tan EK. Parkinson's disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender. Aging (Albany NY). 2022;14(5):2148–73. https://doi.org/10.18632/aging.203932.CrossRefPubMed

133.

Zhang P, Liu B. Association between Parkinson's Disease and Risk of Cancer: A PRISMA-compliant Meta-analysis. ACS Chem Neurosci. 2019;10(10):4430–9. https://doi.org/10.1021/acschemneuro.9b00498.CrossRefPubMed

134.

Zhang X, Guarin D, Mohammadzadehhonarvar N, Chen X, Gao X. Parkinson's disease and cancer: a systematic review and meta-analysis of over 17 million participants. BMJ Open. 2021;11(7):e046329. https://doi.org/10.1136/bmjopen-2020-046329.CrossRefPubMedPubMedCentral

135.

Cui X, Liew Z, Hansen J, Lee PC, Arah OA, Ritz B. Cancers Preceding Parkinson's Disease after Adjustment for Bias in a Danish Population-Based Case-Control Study. Neuroepidemiology. 2019;52(3-4):136–43. https://doi.org/10.1159/000494292.CrossRefPubMed

136.

Oh YS, Yoo SW, Lyoo CH, Lee KS, Kim JS. Premorbid cancer and motor reserve in patients with Parkinson's disease. Sci Rep. 2022;12(1):9254. https://doi.org/10.1038/s41598-022-13322-x.CrossRefPubMedPubMedCentral

137.

Bose A, Petsko GA, Eliezer D. Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms. J Parkinsons Dis. 2018;8(3):385–98. https://doi.org/10.3233/JPD-171263.CrossRefPubMedPubMedCentral

138.

Filippou PS, Outeiro TF. Cancer and Parkinson's Disease: Common Targets, Emerging Hopes. Mov Disord. 2021;36(2):340–6. https://doi.org/10.1002/mds.28425.CrossRefPubMed

139.

Krasowska D, Gerkowicz A, Mlak R, Leziak M, Malecka-Massalska T, Krasowska D. Risk of Nonmelanoma Skin Cancers and Parkinson's Disease-Meta-Analysis and Systematic Review. Cancers (Basel). 2021;13(4) https://doi.org/10.3390/cancers13040587.

140.

Dube U, Ibanez L, Budde JP, Benitez BA, Davis AA, Harari O, Iles MM, Law MH, Brown KM, Me Research, T, Melanoma-Meta-analysis, C, Cruchaga C. Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathol. 2020;139(2):347–64. https://doi.org/10.1007/s00401-019-02110-z.CrossRefPubMed

141.

Ye Q, Wen Y, Al-Kuwari N, Chen X. Association Between Parkinson's Disease and Melanoma: Putting the Pieces Together. Front Aging Neurosci. 2020;12:60. https://doi.org/10.3389/fnagi.2020.00060.CrossRefPubMedPubMedCentral

142.

Mahajan A, Chirra M, Dwivedi AK, Sturchio A, Keeling EG, Marsili L, Espay AJ. Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study. Front Neurol. 2020;11:406. https://doi.org/10.3389/fneur.2020.00406.CrossRefPubMedPubMedCentral

143.

Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Waro B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, et al. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Mov Disord. 2019;34(9):1392–8. https://doi.org/10.1002/mds.27807.CrossRefPubMedPubMedCentral

144.

Waro BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease. Brain Behav. 2018;8(1):e00858. https://doi.org/10.1002/brb3.858.CrossRefPubMed

145.

Sugier PE, Lucotte EA, Domenighetti C, Law MH, Iles MM, Brown K, Amos C, McKay JD, Hung RJ, Karimi M, Bacq-Daian D, Boland-Auge A, Olaso R, Deleuze JF, Lesueur F, Ostroumova E, Kesminiene A, de Vathaire F, Guenel P, et al. Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers. Mov Disord. 2023;38(4):604–15. https://doi.org/10.1002/mds.29337.CrossRefPubMedPubMedCentral

146.

Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C. Understanding the links between cardiovascular disease and Parkinson's disease. Mov Disord. 2020;35(1):55–74. https://doi.org/10.1002/mds.27836.CrossRefPubMed

147.

Zhong Q, Wang S. Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1109914. https://doi.org/10.3389/fnagi.2023.1109914.CrossRefPubMedPubMedCentral

148.

Sanchez-Gomez A, Diaz Y, Duarte-Salles T, Compta Y, Marti MJ. Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study. Parkinsonism Relat Disord. 2021;89:22–7. https://doi.org/10.1016/j.parkreldis.2021.06.002.CrossRefPubMed

149.

Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis. 2012;10(1-4):277–84. https://doi.org/10.1159/000333222.CrossRefPubMed

150.

Wu MC, Xu X, Chen SM, Tyan YS, Chiou JY, Wang YH, Lin LC, Chen CM, Wei JC. Impact of Sjogren's syndrome on Parkinson's disease: A nationwide case-control study. PLoS One. 2017;12(7):e0175836. https://doi.org/10.1371/journal.pone.0175836.CrossRefPubMedPubMedCentral

151.

Chang CC, Lin TM, Chang YS, Chen WS, Sheu JJ, Chen YH, Chen JH. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med. 2018;50(1):83–90. https://doi.org/10.1080/07853890.2017.1412088.CrossRefPubMed

152.

Yeh FC, Chen HC, Chou YC, Lin CL, Kao CH, Lo HY, Liu FC, Yang TY. Positive association of Parkinson's disease with ankylosing spondylitis: a nationwide population-based study. J Transl Med. 2020;18(1):455. https://doi.org/10.1186/s12967-020-02629-w.CrossRefPubMedPubMedCentral

153.

Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. Gut. 2021;70(2):408–17. https://doi.org/10.1136/gutjnl-2020-322429.CrossRefPubMed

154.

Prigent A, Lionnet A, Durieu E, Chapelet G, Bourreille A, Neunlist M, Rolli-Derkinderen M, Derkinderen P. Enteric alpha-synuclein expression is increased in Crohn's disease. Acta Neuropathol. 2019;137(2):359–61. https://doi.org/10.1007/s00401-018-1943-7.CrossRefPubMed

155.

Lin JC, Lin CS, Hsu CW, Lin CL, Kao CH. Association Between Parkinson's Disease and Inflammatory Bowel Disease: a Nationwide Taiwanese Retrospective Cohort Study. Inflamm Bowel Dis. 2016;22(5):1049–55. https://doi.org/10.1097/MIB.0000000000000735.CrossRefPubMed

156.

Park S, Kim J, Chun J, Han K, Soh H, Kang EA, Lee HJ, Im JP, Kim JS. Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson's Disease: A South Korean Nationwide Population-Based Study. J Clin Med. 2019;8(8) https://doi.org/10.3390/jcm8081191.

157.

Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurol. 2018;75(8):939–46. https://doi.org/10.1001/jamaneurol.2018.0605.CrossRefPubMedPubMedCentral

158.

Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. Gut. 2019;68(1):18–24. https://doi.org/10.1136/gutjnl-2017-315666.CrossRefPubMed

159.

Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, Burisch J, Olen O. Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study. Inflamm Bowel Dis. 2019;25(1):111–23. https://doi.org/10.1093/ibd/izy190.CrossRefPubMed

160.

Wan QY, Zhao R, Wu XT. Older patients with IBD might have higher risk of Parkinson's disease. Gut. 2020;69(1):193–4. https://doi.org/10.1136/gutjnl-2018-317103.CrossRefPubMed

161.

Bullich C, Keshavarzian A, Garssen J, Kraneveld A, Perez-Pardo P. Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis. Mov Disord Clin Pract. 2019;6(8):639–51. https://doi.org/10.1002/mdc3.12840.CrossRefPubMedPubMedCentral

162.

Liddle RA. Parkinson's disease from the gut. Brain Res. 2018;1693(Pt B):201–6. https://doi.org/10.1016/j.brainres.2018.01.010.CrossRefPubMedPubMedCentral

163.

Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD. Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol. 2017;8:37. https://doi.org/10.3389/fneur.2017.00037.CrossRefPubMedPubMedCentral

164.

Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology. 2017;88(21):1996–2002. https://doi.org/10.1212/WNL.0000000000003961.CrossRefPubMedPubMedCentral

165.

Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sorensen HT. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol. 2015;78(4):522–9. https://doi.org/10.1002/ana.24448.CrossRefPubMed

166.

Chandra R, Hiniker A, Kuo YM, Nussbaum RL, Liddle RA. alpha-Synuclein in gut endocrine cells and its implications for Parkinson's disease. JCI Insight. 2017;2(12) https://doi.org/10.1172/jci.insight.92295.

167.

Hey G, Nair N, Klann E, Gurrala A, Safarpour D, Mai V, Ramirez-Zamora A, Vedam-Mai V. Therapies for Parkinson's disease and the gut microbiome: evidence for bidirectional connection. Front Aging Neurosci. 2023;15:1151850. https://doi.org/10.3389/fnagi.2023.1151850.CrossRefPubMedPubMedCentral

168.

Palacios N, Wilkinson J, Bjornevik K, Schwarzschild MA, McIver L, Ascherio A, Huttenhower C. Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes. Ann Neurol. 2023;94(3):486–501. https://doi.org/10.1002/ana.26719.CrossRefPubMed

169.

Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR, Payami H. Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun. 2022;13(1):6958. https://doi.org/10.1038/s41467-022-34667-x.CrossRefPubMedPubMedCentral

170.

Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30(3):350–8. https://doi.org/10.1002/mds.26069.CrossRefPubMed

171.

Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351–60. https://doi.org/10.1002/mds.26307.CrossRefPubMed

172.

Boktor JC, Sharon G, Verhagen Metman LA, Hall DA, Engen PA, Zreloff Z, Hakim DJ, Bostick JW, Ousey J, Lange D, Humphrey G, Ackermann G, Carlin M, Knight R, Keshavarzian A, Mazmanian SK. Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome. Mov Disord. 2023;38(3):399–409. https://doi.org/10.1002/mds.29300.CrossRefPubMed

173.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739–49. https://doi.org/10.1002/mds.26942.CrossRefPubMedPubMedCentral

174.

Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol. 2022;18(8):476–95. https://doi.org/10.1038/s41582-022-00681-2.CrossRefPubMed

175.

McGee DJ, Lu XH, Disbrow EA. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease. J Parkinsons Dis. 2018;8(3):367–74. https://doi.org/10.3233/JPD-181327.CrossRefPubMedPubMedCentral

176.

Tan AH, Lim SY, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, et al. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. Mov Disord. 2020;35(12):2250–60. https://doi.org/10.1002/mds.28248.CrossRefPubMed

177.

Emmi A, Sandre M, Porzionato A, Antonini A. Smell deficits in COVID-19 and possible links with Parkinson's disease. Int Rev Neurobiol. 2022;165:91–102. https://doi.org/10.1016/bs.irn.2022.08.001.CrossRefPubMedPubMedCentral

178.

Amruta N, Chastain WH, Paz M, Solch RJ, Murray-Brown IC, Befeler JB, Gressett TE, Longo MT, Engler-Chiurazzi EB, Bix G. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev. 2021;58:1–15. https://doi.org/10.1016/j.cytogfr.2021.02.002.CrossRefPubMedPubMedCentral

179.

Ivan I, Irincu L, Diaconu S, Falup-Pecurariu C. Parkinsonism associated with viral infection. Int Rev Neurobiol. 2022;165:1–16. https://doi.org/10.1016/bs.irn.2022.07.005.CrossRefPubMed

180.

Boura I, Chaudhuri KR. Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far. Mov Disord Clin Pract. 2022;9(5):584–93. https://doi.org/10.1002/mdc3.13461.CrossRefPubMedPubMedCentral

181.

Estupinan D, Nathoo S, Okun MS. The Demise of Poskanzer and Schwab's Influenza Theory on the Pathogenesis of Parkinson's Disease. Parkinsons Dis. 2013;2013:167843. https://doi.org/10.1155/2013/167843.CrossRefPubMedPubMedCentral

182.

Henry J, Smeyne RJ, Jang H, Miller B, Okun MS. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord. 2010;16(9):566–71. https://doi.org/10.1016/j.parkreldis.2010.06.012.CrossRefPubMedPubMedCentral

183.

Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and Risk of Parkinson's Disease. J Parkinsons Dis. 2021;11(1):31–43. https://doi.org/10.3233/JPD-202279.CrossRefPubMedPubMedCentral

184.

Cocoros NM, Svensson E, Szepligeti SK, Vestergaard SV, Szentkuti P, Thomsen RW, Borghammer P, Sorensen HT, Henderson VW. Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurol. 2021;78(12):1461–70. https://doi.org/10.1001/jamaneurol.2021.3895.CrossRefPubMed

185.

Wang H, Liu X, Tan C, Zhou W, Jiang J, Peng W, Zhou X, Mo L, Chen L. Bacterial, viral, and fungal infection-related risk of Parkinson's disease: Meta-analysis of cohort and case-control studies. Brain Behav. 2020;10(3):e01549. https://doi.org/10.1002/brb3.1549.CrossRefPubMedPubMedCentral

186.

Parkinson Progression Marker, I. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629–35. https://doi.org/10.1016/j.pneurobio.2011.09.005.CrossRef

187.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https://doi.org/10.1371/journal.pmed.1001779.CrossRefPubMedPubMedCentral

188.

Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191–204. https://doi.org/10.1016/S1474-4422(23)00404-0.CrossRefPubMed

Titel: Epidemiology of Parkinson’s Disease: An Update
verfasst von: Juan R Deliz
Caroline M. Tanner
Paulina Gonzalez-Latapi
Publikationsdatum: 20.04.2024
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-024-01339-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen